Summary Background Hidradenitis suppurativa (HS) is a chronic, inflammatory condition that can have periodic worsening or flares. Measurement of flare is important because it can inform treatment efficacy; however, it is unclear how HS flare should be defined. Objectives This study reviewed the literature for definitions of HS flare. Methods The PubMed MEDLINE online database was searched on 10 January 2018 and the search was repeated on 8 December 2018 for new publications. Titles and abstracts were screened for inclusion. Subsequently, full articles were screened for inclusion. Papers were included if the publication was a systematic review, clinical trial, cohort study, case report or series, or cross‐sectional study. Studies were excluded if they were journalistic reviews, did not discuss clinical findings of HS or did not use the words ‘flare’, ‘exacerbation’, ‘relapse’ or ‘recurrence’. Results Two hundred and seventy‐four papers were identified and 154 fulfilled the study criteria. Of these, 27 (17.5%) included the term ‘flare’ and 16 (10.4%) included the term ‘exacerbation’. Two of the 27 papers (7%) defined the term flare and both included patient report of changes in symptoms or signs. One of 16 papers (6%) defined exacerbation, which was taken as one new HS lesion. The terms ‘recurrence’ and ‘relapse’ were more apt to be defined: 13% (13 of 100) and 14% (six of 44), respectively. Conclusions The lack of a specific and measurable definition of HS flare is a barrier to assessment of this important outcome. Once a specific and measurable definition is established, validated and reliable measures of HS flare can be incorporated into future studies. What's already known about this topic? Hidradenitis suppurativa (HS) is a chronic, relapsing inflammatory skin condition. The ability to assess flares is important to people who have HS; however, it is unclear how this is defined. HS flare is one of the core outcomes in the core outcome set for HS clinical trials; however, it is unclear how this should be assessed. What does this study add? This literature review reveals the paucity of measurable definitions associated with the use of the term ‘flare’ in the HS literature. It also highlights the variation and lack of a validated and reliable measure of HS flare.
Summary Hidradenitis suppurativa (HS) causes red, painful, draining bumps and tunnels in the skin. About 0.1 to 1% of people have HS in the U.S.A. and Europe. HS is more common in females. HS lesions (affected areas) happen mostly in folds of the body, such as the armpits, under the breast, groin, or buttocks. The lesions can come‐and‐go or last for months or years. HS can have times where it is worse than usual. These have been called ‘flares’. To measure flares in future studies, a definition for a flare is needed. This study was done to find out how flares were defined in past studies. The researchers looked in a database of published articles for studies about HS that mentioned the word ‘flare’ or ‘exacerbation’. The researchers found 274 published studies, and 154 of them were good enough to be included in this study. Twenty‐seven studies had the word ‘flare’ and 16 included the word ‘exacerbation.’ Only two studies included a definition for the word ‘flare’ and only one paper had a definition for the word ‘exacerbation.’ The way to measure a flare (or exacerbation) was by the patient's experience or the clinician's exam of the skin. This review study showed that an HS flare is often not defined in studies, and the definitions are not always the same. A better definition of HS flare needs to be made so that people with HS, clinicians, and researchers can better measure the activity of the HS and the impact of treatments. This summary relates to the study: A narrative review of the definition of ‘flare’ in hidradenitis suppurativa
Invasive squamous cell carcinoma (SCC) of the skin is one of the most common cancers in USA. We sought to determine the predictors for SCCs in a high-risk population of 932 veterans in the Veterans Affairs Keratinocyte Carcinoma Chemoprevention (VAKCC) Trial. Participants enrolled had at least two keratinocyte carcinomas in the 5 years prior to enrollment and were mainly white males with a median age of 71 years. Participants applied either topical fluorouracil cream 5% or vehicle control cream to the face and ears twice daily for up to 4 weeks. The median follow-up duration was 2.8 years. 11.6% developed a new histopathology-confirmed SCC during our trial. The factors that independently predicted a new invasive SCC in descending order were: number of actinic keratosis (AKs) at the beginning of the study, number of prior invasive SCCs, number of prior SCC in situ, no college education and body mass index. The risk for a new SCCs in 2 years was 5%, 12% and 20% for patients with 0, 1 and 2 or more prior SCCs, respectively. The risk for a new SCC in 2 years was 3%, 6% and 14% for patients with 0-2, 3-6 and 7 or more AKs at baseline, respectively. Based on our data, if patients are followed biennially (vs. semiannually), the associated cost of visits over 2 years will be $82.49 vs. $329.96, but the potential risk of delayed diagnosis might be substantial if the patient or their family do not notice and evaluate a new lesion promptly. Our results are a first step in individualizing follow-up schedules for cost-effective management.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.